PA
PACB.US Pacific Biosciences of California
- Market cap
- USD 612M
- P/E
- -
- P/B
- 170.66x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PACB.US undervalued?
Graham numberThe Graham number of Pacific Biosciences of California cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pacific Biosciences of California fundamental analysis
No fundamental analysis for Pacific Biosciences of California yet.
Pacific Biosciences of California stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, b…
Full company profilePacific Biosciences of California financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pacific Biosciences of California annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 90.7M | 93.5M | 78.6M | 90.9M | 78.9M | 131M | 128M | 201M | 154M | 160M | 156M |
| Gross Profit | 44.2M | 34.7M | 25.1M | 34.6M | 32.6M | 58.9M | 49.0M | 52.8M | 37.3M | 50.7M | 51.9M |
| Operating Income | -71.2M | -89.8M | -101M | -101M | -104M | -210M | -307M | -334M | -474M | -558M | -159M |
| EBITDA | -67.3M | -80.8M | -92.9M | -71.6M | 39.0M | -251M | -282M | -271M | -243M | -153M | -106M |
| Net Income | -74.4M | -92.2M | -103M | -84.1M | 29.4M | -181M | -314M | -307M | -310M | -546M | -121M |
| EPS | -0.83 | -0.87 | -0.76 | -0.55 | 0.17 | -0.89 | -1.40 | -1.21 | -1.07 | -1.82 | -0.39 |
| Balance Sheet | |||||||||||
| Total Assets | 138M | 144M | 170M | 148M | 414M | 2.01B | 1.77B | 1.75B | 1.26B | 784M | 721M |
| Total Liabilities | 53.2M | 58.0M | 56.2M | 93.1M | 78.5M | 1.22B | 1.20B | 1.04B | 754M | 779M | 782M |
| Shareholders' Equity | 84.7M | 86.1M | 114M | 54.9M | 335M | 791M | 563M | 701M | 507M | 5.35M | -61.4M |
| Cash & Short-term Investments | 72.0M | 62.9M | 102M | 49.1M | 319M | 1.04B | 772M | 631M | 390M | 280M | 199M |
| Total Debt | 32.7M | 19.9M | 20.9M | 61.7M | 42.0M | 955M | 948M | 934M | 672M | 760M | 705M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -67.9M | -67.5M | -66.4M | -78.3M | 19.5M | -111M | -263M | -267M | -206M | -111M | -217M |
| Capital Expenditure | 8.21M | 10.4M | 1.85M | 2.84M | 1.04M | 5.93M | 16.9M | 8.84M | 6.19M | 2.71M | 7.45M |
| Free Cash Flow | -76.1M | -78.0M | -68.3M | -81.1M | 18.5M | -117M | -280M | -275M | -212M | -114M | -224M |
| Ratios | |||||||||||
| ROE | -87.8% | -107.1% | -89.9% | -153.2% | 8.8% | -22.9% | -55.8% | -43.7% | -61.2% | -10,214.5% | - |
| ROA | -53.9% | -64.0% | -60.2% | -56.9% | 7.1% | -9.0% | -17.8% | -17.6% | -24.6% | -69.7% | -16.8% |
| Net Profit Margin | -82.0% | -98.6% | -130.4% | -92.6% | 37.3% | -138.9% | -244.9% | -153.0% | -201.2% | -341.5% | -77.8% |
| Debt to Equity | 0.39x | 0.23x | 0.18x | 1.12x | 0.13x | 1.21x | 1.68x | 1.33x | 1.33x | 142.07x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pacific Biosciences of California dividends
Pacific Biosciences of California has not paid dividends in the last 9 fiscal years.
Who owns Pacific Biosciences of California
- Insiders 8.97%
- Institutions 67.22%
- Public & others 23.82%
- Shares outstanding 312M
- Free float 306M
Top funds holding PACB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Innovation ETF | 13.3M | 4.26% | -3.15% | Oct 2026 |
| ARK Genomic Revolution ETF | 11.8M | 3.76% | +0.58% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 9.54M | 3.05% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 7.37M | 2.36% | 0.00% | Oct 2026 |
| T. Rowe Price New Horizons | 4.74M | 1.52% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 3.21M | 1.03% | +4.82% | Aug 2026 |
| Amova ARK Pstv Chg Innovt P JPY Acc | 2.87M | 0.92% | -4.21% | Sep 2026 |
| BlackRock Advantage Small Cap Core Instl | 2.59M | 0.83% | +0.89% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 2.57M | 0.82% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 2.22M | 0.71% | -2.40% | Oct 2026 |
| ARK Venture D | 1.73M | 0.55% | +26.14% | Jul 2026 |
| Amova ARK Disruptive Innovation A USD | 1.72M | 0.55% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 1.69M | 0.54% | +4.21% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 1.67M | 0.54% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 1.47M | 0.47% | -10.57% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 975K | 0.31% | 0.00% | Oct 2026 |
| iShares Genomics Immnlgy & Hlthcr ETF | 828K | 0.27% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 769K | 0.25% | +0.11% | Sep 2026 |
| ARK Genomic Revolution ETF A USD Acc | 748K | 0.24% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 713K | 0.23% | +4.02% | Sep 2026 |
Top institutions holding PACB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 32.3M | 10.36% | +27.99% | Jun 2026 |
| ARK Investment Management LLC | 29.8M | 9.54% | -17.90% | Jun 2026 |
| SoftBank Group Corp | 20.5M | 6.55% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 13.4M | 4.29% | +4.86% | Jun 2026 |
| Geode Capital Management, LLC | 7.61M | 2.44% | +9.05% | Jun 2026 |
| Amova Asset Management Americas, Inc | 6.01M | 1.92% | -14.61% | Jun 2026 |
| Sumitomo Mitsui Trust Group Inc | 6.01M | 1.92% | -14.61% | Jun 2026 |
| State Street Corp | 5.96M | 1.91% | -2.62% | Jun 2026 |
| Point72 Asset Management, L.P. | 4.79M | 1.53% | +1,575.64% | Jun 2026 |
| Two Sigma Investments LLC | 4.24M | 1.36% | +20.89% | Jun 2026 |
| D. E. Shaw & Co LP | 4.21M | 1.35% | +15.69% | Jun 2026 |
| Millennium Management LLC | 3.96M | 1.27% | -19.01% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.23M | 1.03% | +226.76% | Jun 2026 |
| Citadel Advisors Llc | 2.85M | 0.91% | +80.57% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.67M | 0.86% | -6.85% | Jun 2026 |
| Charles Schwab Investment Management Inc | 2.65M | 0.85% | +10.26% | Jun 2026 |
| Northern Trust Corp | 2.35M | 0.75% | +10.42% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 2.19M | 0.70% | +10.13% | Jun 2026 |
| Susquehanna International Group, LLP | 2.13M | 0.68% | +23.85% | Jun 2026 |
| Longaeva Partners L.P. | 2.12M | 0.68% | 0.00% | Jun 2026 |
Pacific Biosciences of California company profile
- Company name
- Pacific Biosciences of California
- Ticker
- PACB.US
- Exchange
- USA Stocks
- Listed since
- Oct 27, 2010
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 485
- Fiscal year end
- December
- Address
- 1305 O?Brien Drive, Menlo Park, CA, United States, 94025
- Phone
- 650 521 8000
- Website
- pacb.com
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Pacific Biosciences of California management
7- Mr. Mark Van Oene Ph.D.CEO, President, Director & Interim CFO · born 1973
- Mr. Christian O. Henry M.B.A.Senior Business Advisor & Director · born 1968
- Mr. James R. Gibson IIAdvisor · born 1970
- Dr. Stephen Turner Ph.D.Co-Founder · born 1968
- Mr. William E. MeyerChief Accounting Officer & Corporate Controller · born 1962
- Dr. Brett Atkins J.D., Ph.D.General Counsel & Corporate Secretary
- Ms. Natalie WelchChief People Officer